The FDA and the COVID‐19: A political economy perspective
Author
Abstract
Suggested Citation
DOI: 10.1002/soej.12494
Download full text from publisher
References listed on IDEAS
- Simon Mongey & Laura Pilossoph & Alex Weinberg, 2020.
"Which Workers Bear the Burden of Social Distancing Policies?,"
Working Papers
2020-51, Becker Friedman Institute for Research In Economics.
- Simon Mongey & Laura Pilossoph & Alexander Weinberg, 2020. "Which Workers Bear the Burden of Social Distancing Policies?," Liberty Street Economics 20200529b, Federal Reserve Bank of New York.
- Isakov, Leah & Lo, Andrew W. & Montazerhodjat, Vahid, 2019.
"Is the FDA too conservative or too aggressive?: A Bayesian decision analysis of clinical trial design,"
Journal of Econometrics, Elsevier, vol. 211(1), pages 117-136.
- Vahid Montazerhodjat & Andrew W. Lo, 2015. "Is the FDA Too Conservative or Too Aggressive?: A Bayesian Decision Analysis of Clinical Trial Design," NBER Working Papers 21499, National Bureau of Economic Research, Inc.
- Alexander Chudik & M. Hashem Pesaran & Alessandro Rebucci, 2020.
"Voluntary and Mandatory Social Distancing: Evidence on COVID-19 Exposure Rates from Chinese Provinces and Selected Countries,"
NBER Working Papers
27039, National Bureau of Economic Research, Inc.
- Alexander Chudik & M. Hashem Pesaran & Alessandro Rebucci, 2020. "Voluntary and Mandatory Social Distancing: Evidence on COVID-19 Exposure Rates from Chinese Provinces and Selected Countries," Globalization Institute Working Papers 382, Federal Reserve Bank of Dallas.
- Rebucci, Alessandro & Chudik, Alexander & Pesaran, M. Hashem, 2020. "Voluntary and Mandatory Social Distancing: Evidence on COVID-19 Exposure Rates from Chinese Provinces and Selected Countries," CEPR Discussion Papers 14646, C.E.P.R. Discussion Papers.
- Alexander Chudik & M. Hashem Pesaran & Alessandro Rebucci, 2020. "Voluntary and Mandatory Social Distancing: Evidence on Covid-19 Exposure Rates from Chinese Provinces and Selected Countries," CESifo Working Paper Series 8243, CESifo.
- Nicolás Cachanosky & Bryan P. Cutsinger & Thomas L. Hogan & William J. Luther & Alexander W. Salter, 2021. "The Federal Reserve's response to the COVID‐19 contraction: An initial appraisal," Southern Economic Journal, John Wiley & Sons, vol. 87(4), pages 1152-1174, April.
- Peltzman, Sam, 1973. "An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments," Journal of Political Economy, University of Chicago Press, vol. 81(5), pages 1049-1091, Sept.-Oct.
- Angus C. Chu, 2008.
"Special Interest Politics And Intellectual Property Rights: An Economic Analysis Of Strengthening Patent Protection In The Pharmaceutical Industry,"
Economics and Politics, Wiley Blackwell, vol. 20(2), pages 185-215, June.
- Chu, Angus C., 2007. "Special Interest Politics and Intellectual Property Rights: An Economic Analysis of Strengthening Patent Protection in the Pharmaceutical Industry," MPRA Paper 4349, University Library of Munich, Germany.
- Paul T E Cusack, 2020. "On Pain," Biomedical Journal of Scientific & Technical Research, Biomedical Research Network+, LLC, vol. 31(3), pages 24253-24254, October.
- Facundo Piguillem & Liyan Shi, 2022.
"Optimal Covid-19 Quarantine and Testing Policies,"
The Economic Journal, Royal Economic Society, vol. 132(647), pages 2534-2562.
- Facundo Piguillem & Liyan Shi, 2020. "Optimal COVID-19 Quarantine and Testing Policies," EIEF Working Papers Series 2004, Einaudi Institute for Economics and Finance (EIEF), revised Apr 2020.
- Piguillem, Facundo & Shi, Liyan, 2020. "Optimal COVID-19 Quarantine and Testing Policies," CEPR Discussion Papers 14613, C.E.P.R. Discussion Papers.
- Philipson, Tomas & Berndt, Ernst R. & Gottschalk, Adrian H.B. & Sun, Eric, 2008.
"Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts,"
Journal of Public Economics, Elsevier, vol. 92(5-6), pages 1306-1325, June.
- Philipson, Tomas J. & Berndt, Ernst R. & Gottschalk, Adrian H. B. & Sun, Eric, 2007. "Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts," Working Papers 217, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G. & Lasagna, Louis, 1991. "Cost of innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 10(2), pages 107-142, July.
- March, Raymond J., 2017. "Skin in the game: comparing the private and public regulation of isotretinoin," Journal of Institutional Economics, Cambridge University Press, vol. 13(3), pages 649-672, September.
- Borgonovi, Francesca & Andrieu, Elodie, 2020. "Bowling together by bowling alone: Social capital and COVID-19," Social Science & Medicine, Elsevier, vol. 265(C).
- Dale H. Gieringer, 1985. "The Safety and Efficacy of New Drug Approval," Cato Journal, Cato Journal, Cato Institute, vol. 5(1), pages 177-201, Spring/Su.
- Tomas J. Philipson & Eric Sun, 2008.
"Is the Food And Drug Administration Safe And Effective?,"
Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
- Tomas J. Philipson & Eric Sun, 2007. "Is the Food and Drug Administration Safe and Effective?," NBER Working Papers 13561, National Bureau of Economic Research, Inc.
- Philipson, Tomas J. & Sun, Eric, 2007. "Is the Food and Drug Administration Safe and Effective?," Working Papers 218, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Kevin Z. Chen & Rui Mao, 2020. "Fire lines as fault lines: increased trade barriers during the COVID-19 pandemic further shatter the global food system," Food Security: The Science, Sociology and Economics of Food Production and Access to Food, Springer;The International Society for Plant Pathology, vol. 12(4), pages 735-738, August.
- Henry Grabowski & Y. Richard Wang, 2008. "Do Faster Food and Drug Administration Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act," Journal of Law and Economics, University of Chicago Press, vol. 51(2), pages 377-406, May.
- Simon Mongey & Laura Pilossoph & Alexander Weinberg, 2021.
"Which workers bear the burden of social distancing?,"
The Journal of Economic Inequality, Springer;Society for the Study of Economic Inequality, vol. 19(3), pages 509-526, September.
- Simon Mongey & Laura Pilossoph & Alex Weinberg, 2020. "Which Workers Bear the Burden of Social Distancing Policies?," Working Papers 2020-51, Becker Friedman Institute for Research In Economics.
- Simon Mongey & Laura Pilossoph & Alex Weinberg, 2020. "Which Workers Bear the Burden of Social Distancing?," NBER Working Papers 27085, National Bureau of Economic Research, Inc.
- Grabowski, Henry G & Vernon, John M & Thomas, Lacy Glenn, 1978. "Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry," Journal of Law and Economics, University of Chicago Press, vol. 21(1), pages 133-163, April.
- Sumedha Gupta & Thuy D. Nguyen & Felipe Lozano Rojas & Shyam Raman & Byungkyu Lee & Ana Bento & Kosali I. Simon & Coady Wing, 2020. "Tracking Public and Private Responses to the COVID-19 Epidemic: Evidence from State and Local Government Actions," NBER Working Papers 27027, National Bureau of Economic Research, Inc.
- Wiggins, Steven N, 1981. "Product Quality Regulation and New Drug Introductions: Some New Evidence from the 1970s," The Review of Economics and Statistics, MIT Press, vol. 63(4), pages 615-619, November.
- Anna Chorniy & James Bailey & Abdulkadir Civan & Michael Maloney, 2021. "Regulatory review time and pharmaceutical research and development," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 113-128, January.
- David Dranove & David Meltzer, 1994. "Do Important Drugs Reach the Market Sooner?," RAND Journal of Economics, The RAND Corporation, vol. 25(3), pages 402-423, Autumn.
- Rosolino A. Candela & Vincent Geloso, 2021. "Economic freedom, pandemics, and robust political economy," Southern Economic Journal, John Wiley & Sons, vol. 87(4), pages 1250-1266, April.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- David J. Hebert & Michael D. Curry, 2022. "Optimal lockdowns," Public Choice, Springer, vol. 193(3), pages 263-274, December.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Mary Olson, 2013. "Eliminating the U.S. drug lag: Implications for drug safety," Journal of Risk and Uncertainty, Springer, vol. 47(1), pages 1-30, August.
- Boakye, Derrick & Sarpong, David & Mordi, Chima, 2022. "Regulatory review of new product innovation: Conceptual clarity and future research directions," Technological Forecasting and Social Change, Elsevier, vol. 175(C).
- Simone Ghislandi & Michael Kuhn, 2016.
"Asymmetric information in the regulation of the access to markets,"
Department of Economics Working Papers
wuwp219, Vienna University of Economics and Business, Department of Economics.
- Ghislandi, Simone & Kuhn, Michael, 2016. "Asymmetric information in the regulation of the access to markets," Department of Economics Working Paper Series 219, WU Vienna University of Economics and Business.
- Tomas J. Philipson & Eric Sun, 2008.
"Is the Food And Drug Administration Safe And Effective?,"
Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
- Tomas J. Philipson & Eric Sun, 2007. "Is the Food and Drug Administration Safe and Effective?," NBER Working Papers 13561, National Bureau of Economic Research, Inc.
- Philipson, Tomas J. & Sun, Eric, 2007. "Is the Food and Drug Administration Safe and Effective?," Working Papers 218, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Aum, Sangmin & Lee, Sang Yoon (Tim) & Shin, Yongseok, 2021.
"Inequality of fear and self-quarantine: Is there a trade-off between GDP and public health?,"
Journal of Public Economics, Elsevier, vol. 194(C).
- Lee, Sang Yoon (Tim) & Aum, Sangmin & Shin, Yongseok, 2020. "Inequality of Fear and Self-Quarantine: Is There a Trade-off between GDP and Public Health?," CEPR Discussion Papers 14679, C.E.P.R. Discussion Papers.
- Sangmin Aum & Sang Yoon (Tim) Lee & Yongseok Shin, 2020. "Inequality of Fear and Self-Quarantine: Is There a Trade-off between GDP and Public Health?," NBER Working Papers 27100, National Bureau of Economic Research, Inc.
- Sangmin Aum & Sang Yoon (Tim) Lee & Yongseok Shin, 2020. "Inequality of Fear and Self-Quarantine: Is There a Trade-off between GDP and Public Health?," Working Papers 902, Queen Mary University of London, School of Economics and Finance.
- Tomas J. Philipson & George Zanjani, 2013. "Economic Analysis of Risk and Uncertainty induced by Health Shocks: A Review and Extension," NBER Working Papers 19005, National Bureau of Economic Research, Inc.
- Anna Chorniy & James Bailey & Abdulkadir Civan & Michael Maloney, 2021. "Regulatory review time and pharmaceutical research and development," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 113-128, January.
- Etienne Farvaque & Hira Iqbal & Nicolas Ooghe, 2020. "Health politics? Determinants of US states’ reactions to COVID-19," Post-Print hal-03128875, HAL.
- Henry Grabowski & Y. Richard Wang, 2008. "Do Faster Food and Drug Administration Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act," Journal of Law and Economics, University of Chicago Press, vol. 51(2), pages 377-406, May.
- Houštecká, Anna & Koh, Dongya & Santaeulàlia-Llopis, Raül, 2021. "Contagion at work: Occupations, industries and human contact," Journal of Public Economics, Elsevier, vol. 200(C).
- Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
- Christian Moser & Pierre Yared, 2022.
"Pandemic Lockdown: The Role of Government Commitment,"
Review of Economic Dynamics, Elsevier for the Society for Economic Dynamics, vol. 46, pages 27-50, October.
- Christian A. Moser & Pierre Yared, 2020. "Pandemic Lockdown: The Role of Government Commitment," NBER Working Papers 27062, National Bureau of Economic Research, Inc.
- Christian Moser & Pierre Yared, 2021. "Pandemic Lockdown: The Role of Government Commitment," Staff Report 627, Federal Reserve Bank of Minneapolis.
- Moser, Christian & Yared, Pierre, 2020. "Pandemic Lockdown: The Role of Government Commitment," CEPR Discussion Papers 16384, C.E.P.R. Discussion Papers.
- Moser, Christian & Yared, Pierre, 2020. "Pandemic Lockdown: The Role of Government Commitment," MPRA Paper 99804, University Library of Munich, Germany.
- Christian Moser & Pierre Yared, 2021. "Online Appendix to "Pandemic Lockdown: The Role of Government Commitment"," Online Appendices 20-442, Review of Economic Dynamics.
- Christian Moser & Pierre Yared, 2021. "Code and data files for "Pandemic Lockdown: The Role of Government Commitment"," Computer Codes 20-442, Review of Economic Dynamics.
- Alipour, Jean-Victor & Fadinger, Harald & Schymik, Jan, 2021. "My home is my castle – The benefits of working from home during a pandemic crisis," Journal of Public Economics, Elsevier, vol. 196(C).
- Kong, Edward & Prinz, Daniel, 2020. "Disentangling policy effects using proxy data: Which shutdown policies affected unemployment during the COVID-19 pandemic?," Journal of Public Economics, Elsevier, vol. 189(C).
- Mauro Caselli & Andrea Fracasso & Sergio Scicchitano, 2022. "From the lockdown to the new normal: individual mobility and local labor market characteristics following the COVID-19 pandemic in Italy," Journal of Population Economics, Springer;European Society for Population Economics, vol. 35(4), pages 1517-1550, October.
- Dizioli, Allan & Pinheiro, Roberto, 2021.
"Information and inequality in the time of a pandemic,"
Journal of Economic Dynamics and Control, Elsevier, vol. 130(C).
- Allan Dizioli & Roberto Pinheiro, 2020. "Information and Inequality in the Time of a Pandemic," Working Papers 20-25, Federal Reserve Bank of Cleveland.
- Allan Dizioli & Roberto Pinheiro, 2020. "Information and Inequality in the Time of a Pandemic," IMF Working Papers 2020/188, International Monetary Fund.
- Andrew Atkeson & Michael Droste & Michael J. Mina & James H. Stock, 2020.
"Economic Benefits of COVID-19 Screening Tests,"
Staff Report
616, Federal Reserve Bank of Minneapolis.
- Andrew Atkeson & Michael C. Droste & Michael Mina & James H. Stock, 2020. "Economic Benefits of COVID-19 Screening Tests," NBER Working Papers 28031, National Bureau of Economic Research, Inc.
- Danzon, Patricia M. & Nicholson, Sean & Pereira, Nuno Sousa, 2005.
"Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances,"
Journal of Health Economics, Elsevier, vol. 24(2), pages 317-339, March.
- Patricia M. Danzon & Sean Nicholson & Nuno Sousa Pereira, 2003. "Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances," NBER Working Papers 9615, National Bureau of Economic Research, Inc.
- Jung, Juergen & Manley, James & Shrestha, Vinish, 2021.
"Coronavirus infections and deaths by poverty status: The effects of social distancing,"
Journal of Economic Behavior & Organization, Elsevier, vol. 182(C), pages 311-330.
- Juergen Jung & James Manley & Vinish Shrestha, 2020. "Coronavirus Infections and Deaths by Poverty Status: The Effects of Social Distancing," Working Papers 2020-03, Towson University, Department of Economics, revised Dec 2020.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:soecon:v:87:y:2021:i:4:p:1210-1228. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: https://doi.org/10.1002/(ISSN)2325-8012 .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.